Individuals in Canada who are currently receiving or have previously received belantamab mafodotin for multiple myeloma (MM) may be eligible to participate in a research interview study.
This study aims to better understand patients’ experiences with belantamab mafodotin, including its impact on overall well-being, quality of life, and multiple myeloma symptoms. Participation involves a one-hour interview conducted via Zoom or telephone, based on participant preference. Those who complete the interview will receive $80 CAD as compensation for their time.
Who is eligible?
Participants must:
- Be living in Canada
- Be 18 years of age or older
- Be fluent in English
- Have been diagnosed with multiple myeloma by a physician
- Have access to a phone, tablet, laptop, or desktop computer
- Have received or be currently receiving belantamab mafodotin in Canada as part of the ALGONQUIN study
Individuals are not eligible if:
- They have not received the treatment within the past three years
- They have been diagnosed with another type of cancer and/or are currently receiving treatment for another cancer
Interested in participating?
To determine eligibility, participants will be asked to complete a brief 15-minute phone screening.
Please email MMStudy@broadstreetheor.com with your availability (including time zone) for a short call within the next few days and include your phone number. Phone numbers will be used solely for scheduling purposes and will not be retained or shared with any third party.
Your experience can help inform future research and improve understanding of treatment impact for people living with multiple myeloma.